Table 1.
Numbers of Cells Analyzed for Polarity Designation and for Actin Organization
| SMC | Treatment | n |
|---|---|---|
| Analyzed for polarity designation | ||
| Medial | BIM I | 892 |
| Medial | Control | 2355 |
| Neointimal | BIM I | 778 |
| Neointimal | Control | 2761 |
| Neointimal | Noncoding siRNA | 568 |
| Neointimal | siRNA for RHAMM | 614 |
| Neointimal | siRNA for ARPC5 | 635 |
| Medial | Noncoding siRNA | 589 |
| Medial | siRNA for RHAMM | 601 |
| Medial | siRNA for ARPC5 | 616 |
| Neointimal | Ly-333531 | 214 |
| Neointimal | Rottlerin | 199 |
| Neointimal | PKCε inhibitory peptide | 230 |
| Neointimal | PKCζ inhibitory peptide | 207 |
| Neointimal | PKC scrambled peptide substrate | 187 |
| Neointimal | LiCl | 121 |
| Analyzed for actin organization | ||
| Neointimal | Control | 1689 |
| Neointimal | siRNA for ARPC5 | 1176 |
| Neointimal | siRNA for RHAMM | 1035 |
| Neointimal | PKC inhibitor BIM I | 1784 |